Abstract
Diuretics play an essential role in modern cardiovascular therapy, and are currently recommended for the treatment of congestive heart failure. Torasemide has been developed as a newer type of loop diuretic with a longer halflife, longer duration of action, and higher bioavailability compared to the most commonly used loop diuretic, furosemide. Torasemide also appears to have additional actions beyond the pure diuretic effect, such as anti-aldosterone effect and vasorelaxation effect. Studies have also investigated whether the superior pharmacokinetics and pharmacological activity of torasemide result in a favorable clinical outcome. Their results have indicated that, in comparison with furosemide, torasemide improves left ventricular function, reduces mortality as well as the frequency and duration of heart failurerelated hospitalization, and improves quality of life, exercise tolerance and NYHA functional class in patients with congestive heart failure. Thus, torasemide appears to be a promising loop diuretic that contributes to a better management of patients with heart failure. Definitive clinical trials in a double-blind fashion are warranted.
Keywords: Diuretics, furosemide, heart Failure, torasemide
Cardiovascular & Hematological Disorders-Drug Targets
Title: Torasemide for the Treatment of Heart Failure
Volume: 8 Issue: 2
Author(s): Hirotaka Ishido and Hideaki Senzaki
Affiliation:
Keywords: Diuretics, furosemide, heart Failure, torasemide
Abstract: Diuretics play an essential role in modern cardiovascular therapy, and are currently recommended for the treatment of congestive heart failure. Torasemide has been developed as a newer type of loop diuretic with a longer halflife, longer duration of action, and higher bioavailability compared to the most commonly used loop diuretic, furosemide. Torasemide also appears to have additional actions beyond the pure diuretic effect, such as anti-aldosterone effect and vasorelaxation effect. Studies have also investigated whether the superior pharmacokinetics and pharmacological activity of torasemide result in a favorable clinical outcome. Their results have indicated that, in comparison with furosemide, torasemide improves left ventricular function, reduces mortality as well as the frequency and duration of heart failurerelated hospitalization, and improves quality of life, exercise tolerance and NYHA functional class in patients with congestive heart failure. Thus, torasemide appears to be a promising loop diuretic that contributes to a better management of patients with heart failure. Definitive clinical trials in a double-blind fashion are warranted.
Export Options
About this article
Cite this article as:
Ishido Hirotaka and Senzaki Hideaki, Torasemide for the Treatment of Heart Failure, Cardiovascular & Hematological Disorders-Drug Targets 2008; 8 (2) . https://dx.doi.org/10.2174/187152908784533685
DOI https://dx.doi.org/10.2174/187152908784533685 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences FKBP Ligands as Novel Therapeutics for Neurological Disorders
Mini-Reviews in Medicinal Chemistry TRAIL Gene Therapy: From Preclinical Development to Clinical Application
Current Gene Therapy Pharmacological Manipulation of Peripheral Vascular Resistance in Single Ventricle Patients (Stages I, II, and III of Palliation)
Current Vascular Pharmacology Salutary Properties of YC-1 in the Cardiovascular and Hematological Systems
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Essential Hypertension, Cerebral White Matter Pathology and Ischemic Stroke
Current Medicinal Chemistry Therapeutic Interventions to Renin-Angiotensin-Aldosterone System, and Vascular Redox State
Recent Patents on Cardiovascular Drug Discovery Ultrasound Contrast Agents: Updated Data on Safety Profile
Current Pharmaceutical Design Historical Aspects and Relevance of the Human Coronary Collateral Circulation
Current Cardiology Reviews Inhibitory Effect on Replicative DNA Polymerases, Human Cancer Cell Proliferation, and In Vivo Anti-Tumor Activity by Glycolipids from Spinach
Current Medicinal Chemistry The Deadly Quartet (Covid-19, Old Age, Lung Disease, and Heart Failure) Explains Why Coronavirus-Related Mortality in Northern Italy Was So High
Current Cardiology Reviews Pathophysiological Roles of Nitric Oxide: In the Heart and the Coronary Vasculature
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents It Takes Two to Tango: The Structure and Function of LIM, RING, PHD and MYND Domains
Current Pharmaceutical Design Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets MR Spectroscopy in Metabolic Profiling Studies of Stem Cells
Current Medical Imaging Neurocognitive Monitoring and Care During Pediatric Cardiopulmonary Bypass — Current and Future Directions
Current Cardiology Reviews Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure
Current Cardiology Reviews